4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $29.56.

Several equities research analysts recently commented on the company. Chardan Capital lowered their price target on 4D Molecular Therapeutics from $28.00 to $25.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Bank of America dropped their price target on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating on the stock in a research note on Monday, March 10th. Barclays cut their price target on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. The Goldman Sachs Group decreased their price objective on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating for the company in a report on Friday, May 9th. Finally, Royal Bank of Canada lowered their target price on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating on the stock in a research report on Monday, March 3rd.

4D Molecular Therapeutics Price Performance

FDMT traded down $0.04 on Friday, reaching $3.83. 251,820 shares of the company traded hands, compared to its average volume of 829,697. The company has a market cap of $177.42 million, a price-to-earnings ratio of -1.34 and a beta of 2.84. The stock's 50 day moving average price is $3.24 and its 200-day moving average price is $4.71. 4D Molecular Therapeutics has a 52-week low of $2.24 and a 52-week high of $28.93.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.02). As a group, equities research analysts forecast that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Millennium Management LLC increased its stake in shares of 4D Molecular Therapeutics by 1,607.1% in the fourth quarter. Millennium Management LLC now owns 1,420,723 shares of the company's stock worth $7,913,000 after purchasing an additional 1,337,497 shares during the period. BNP Paribas Financial Markets bought a new position in 4D Molecular Therapeutics in the 4th quarter worth approximately $532,000. Rhumbline Advisers lifted its holdings in shares of 4D Molecular Therapeutics by 5.3% during the fourth quarter. Rhumbline Advisers now owns 73,431 shares of the company's stock worth $409,000 after buying an additional 3,675 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of 4D Molecular Therapeutics by 139.2% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,354 shares of the company's stock valued at $364,000 after acquiring an additional 38,031 shares during the period. Finally, Vanguard Group Inc. grew its stake in shares of 4D Molecular Therapeutics by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 2,860,508 shares of the company's stock worth $15,933,000 after acquiring an additional 92,791 shares during the last quarter. Institutional investors and hedge funds own 99.27% of the company's stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.